RYTM vs. VKTX

Last updated Apr 1, 2026

Compare and contrast key facts about Rhythm Pharmaceuticals, Inc. (RYTM) and Viking Therapeutics, Inc. (VKTX).

Performance

RYTM vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rhythm Pharmaceuticals, Inc. (RYTM) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

RYTM vs. VKTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
RYTM Rhythm Pharmaceuticals, Inc.	-18.75%	91.21%	21.78%	57.86%	191.78%	-66.43%	29.49%	-14.58%	-7.50%	-3.13%
VKTX Viking Therapeutics, Inc.	-7.50%	-12.57%	116.23%	97.98%	104.35%	-18.29%	-29.80%	4.84%	88.42%	117.11%

Fundamentals

Market Cap RYTM : $5.82B VKTX : $3.71B
EPS RYTM : -$3.11 VKTX : -$3.19
PB Ratio RYTM : 717.00 VKTX : 5.80
Total Revenue (TTM) RYTM : $189.76M VKTX : $0.00
Gross Profit (TTM) RYTM : $170.27M VKTX : -$208.00K
EBITDA (TTM) RYTM : -$178.54M VKTX : -$393.01M

Returns By Period

In the year-to-date period, RYTM achieves a -18.75% return, which is significantly lower than VKTX's -7.50% return.

RYTM

• 1D: 12.58%
• 1M: -6.21%
• YTD: -18.75%
• 6M: -13.88%
• 1Y: 64.19%
• 3Y*: 69.56%
• 5Y*: 31.36%
• 10Y*: —

VKTX

• 1D: 8.76%
• 1M: -3.84%
• YTD: -7.50%
• 6M: 23.82%
• 1Y: 34.74%
• 3Y*: 25.03%
• 5Y*: 38.96%
• 10Y*: 36.40%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RYTM vs. VKTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RYTM

RYTM Risk / Return Rank: 77
RYTM Sharpe Ratio Rank: 76
RYTM Sortino Ratio Rank: 81
RYTM Omega Ratio Rank: 75
RYTM Calmar Ratio Rank: 73
RYTM Martin Ratio Rank: 79

VKTX

VKTX Risk / Return Rank: 59
VKTX Sharpe Ratio Rank: 58
VKTX Sortino Ratio Rank: 59
VKTX Omega Ratio Rank: 63
VKTX Calmar Ratio Rank: 56
VKTX Martin Ratio Rank: 57

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RYTM vs. VKTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rhythm Pharmaceuticals, Inc. (RYTM) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RYTM	VKTX	Difference
Sharpe ratio Return per unit of total volatility	1.06	0.44	+0.62
Sortino ratio Return per unit of downside risk	2.13	1.10	+1.03
Omega ratio Gain probability vs. loss probability	1.25	1.17	+0.08
Calmar ratio Return relative to maximum drawdown	1.65	0.60	+1.06
Martin ratio Return relative to average drawdown	5.55	1.32	+4.23
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RYTM vs. VKTX - Sharpe Ratio Comparison

The current RYTM Sharpe Ratio is 1.06, which is higher than the VKTX Sharpe Ratio of 0.44. The chart below compares the historical Sharpe Ratios of RYTM and VKTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RYTM	VKTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.06	0.44	+0.62
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.41	0.39	+0.03
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.37	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.19	0.12	+0.07

Correlation

The correlation between RYTM and VKTX is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RYTM vs. VKTX - Dividend Comparison

Neither RYTM nor VKTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RYTM vs. VKTX - Drawdown Comparison

The maximum RYTM drawdown since its inception was -92.10%, roughly equal to the maximum VKTX drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for RYTM and VKTX.

Drawdown Indicators

	RYTM	VKTX	Difference
Max Drawdown Largest peak-to-trough decline	-92.10%	-90.41%	-1.69%
Max Drawdown (1Y) Largest decline over 1 year	-35.54%	-45.14%	+9.60%
Max Drawdown (5Y) Largest decline over 5 years	-86.16%	-78.86%	-7.30%
Max Drawdown (10Y) Largest decline over 10 years	—	-89.26%	—
Current Drawdown Current decline from peak	-26.06%	-65.57%	+39.51%
Average Drawdown Average peak-to-trough decline	-32.33%	-59.92%	+27.59%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.58%	20.31%	-9.73%

Volatility

RYTM vs. VKTX - Volatility Comparison

Rhythm Pharmaceuticals, Inc. (RYTM) has a higher volatility of 19.66% compared to Viking Therapeutics, Inc. (VKTX) at 18.20%. This indicates that RYTM's price experiences larger fluctuations and is considered to be riskier than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RYTM	VKTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.66%	18.20%	+1.46%
Volatility (6M) Calculated over the trailing 6-month period	36.17%	45.65%	-9.48%
Volatility (1Y) Calculated over the trailing 1-year period	60.78%	78.68%	-17.90%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	76.51%	101.68%	-25.17%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	71.45%	99.00%	-27.55%

Financials